The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant attention within the United Kingdom , prompting a notable shift in hormone trends. Obtaining these treatments remains a complex landscape, with public healthcare system coverage currently limited and independent providers offering therapy at a high